Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regulus Therapeutics Inc.    RGLS

REGULUS THERAPEUTICS INC.

(RGLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/05/2021 04/06/2021 04/07/2021 04/08/2021 04/09/2021 Date
1.51(c) 1.48(c) 1.43(c) 1.49(c) 1.38(c) Last
944 313 664 864 588 991 768 394 690 415 Volume
-4.43% -1.99% -3.38% +4.20% -7.38% Change
More quotes
Financials (USD)
Sales 2021 0,04 M - -
Net income 2021 -24,7 M - -
Net cash position 2021 0,01 M - -
P/E ratio 2021 -3,89x
Yield 2021 -
Sales 2022 0,04 M - -
Net income 2022 -26,9 M - -
Net Debt 2022 24,7 M - -
P/E ratio 2022 -3,68x
Yield 2022 -
Capitalization 100 M 100 M -
EV / Sales 2021 2 779x
EV / Sales 2022 3 465x
Nbr of Employees 24
Free-Float 49,4%
More Financials
Company
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is... 
More about the company
Notations Surperformance© of Regulus Therapeutics Inc.
Trading Rating : Investor Rating :
More Ratings
All news about REGULUS THERAPEUTICS INC.
04/07REGULUS THERAPEUTICS  : to Present at the 20th Annual Needham Virtual Healthcare..
PR
03/09REGULUS : Q4 Earnings Snapshot
AQ
03/09REGULUS THERAPEUTICS INC.  : Results of Operations and Financial Condition, Fina..
AQ
03/09REGULUS THERAPEUTICS  : Q4 Loss Narrows, Revenue Climbs
MT
03/09REGULUS THERAPEUTICS  : Reports Fourth Quarter and Year-End 2020 Financial Resul..
PR
03/05REGULUS THERAPEUTICS  : to Present at the H.C. Wainwright Global Life Sciences C..
PR
02/17REGULUS THERAPEUTICS INC.  : Entry into a Material Definitive Agreement (form 8-..
AQ
02/17REGULUS THERAPEUTICS  : Wedbush Adjusts Price Target on Regulus Therapeutics to ..
MT
02/10REGULUS THERAPEUTICS  : Completes Enrollment in First Cohort of Phase 1b Clinica..
MT
02/10REGULUS THERAPEUTICS  : Announces Completion of Enrollment in First Cohort of Ph..
PR
01/28REGULUS THERAPEUTICS INC.  : Change in Directors or Principal Officers (form 8-K..
AQ
01/05REGULUS THERAPEUTICS  : to Present at the H.C. Wainwright Virtual BioConnect Con..
PR
01/04REGULUS THERAPEUTICS  : Files Shelf for Up to 47.4 Million Common Shares on Beha..
MT
2020REGULUS THERAPEUTICS  : Thinking about buying stock in Inseego Corp, Ampio Pharm..
PR
2020REGULUS THERAPEUTICS  : Insiders Make Significant purchases of Regulus Therapeut..
MT
More news
News in other languages on REGULUS THERAPEUTICS INC.
04/07DGAP-HV  : Fresenius Medical Care AG & Co. KGaA: -4-
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 1,25 $
Last Close Price 1,38 $
Spread / Highest target 44,9%
Spread / Average Target -9,42%
Spread / Lowest Target -63,8%
EPS Revisions
Managers and Directors
NameTitle
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGULUS THERAPEUTICS INC.2.22%100
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 997
IQVIA HOLDINGS INC.15.90%39 822
CELLTRION, INC.-13.23%37 705
SEAGEN INC.-18.44%25 900